NOVEL COMPOUND USEFUL FOR THE TREATEMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
申请人:MENET Christel Jeanne Marie
公开号:US20160213666A1
公开(公告)日:2016-07-28
A pyrazolopyridine compound according to Formula I, able to inhibit JAK is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant JAK activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
公开了一种按照式I的吡唑吡啶化合物,能够抑制JAK,以及其药学上可接受的盐、其溶剂化物、药学上可接受的盐的溶剂化物和其生物活性代谢物。该化合物可以制备为药物组合物,并可用于哺乳动物,包括人类的各种情况的治疗或预防,特别是与畸变的JAK活性有关的情况,包括但不限于过敏、炎症状况、自身免疫疾病、增殖性疾病、移植排斥、涉及软骨周转障碍的疾病、先天性软骨畸形以及与IL6过度分泌有关的疾病。